Fernando J. Muzzio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fernando J. Muzzio


Fernando J. Muzzio, PhD, is a Pharmtech editorial advisory board (EAB) member

Fernando J. Muzzio, PhD
Director, NSF Engineering Research Center on Structured Organic Particulate Systems, Department of
Chemical and Biochemical
Engineering,
Rutgers University

Fernando J. Muzzio is a professor in the Department of Chemical and Biochemical Engineering at Rutgers University. He currently serves as the director of the NSF Engineering Research Center on Structured Organic Particulate Systems, the director of the NSF-NIH Nanopharmaceutical Engineering IGERT training program, the co-chair of the technology subcommittee for the National Institute for Pharmaceutical Technology and Education. He is a member of the editorial boards of Pharmaceutical Technology and the Journal for Pharmaceutical Innovation.

Muzzio has published more than 140 peer-reviewed papers, written eight book chapters, presented numerous papers at major technical meetings, and holds six patents. He has been invited to present at numerous academic, industry, and federal seminars.

He received his PhD from the University of Massachusetts at Amherst in chemical engineering in 1991. His thesis was titled: "Non-Linearity, Chaos, and Self-Similarity: Effects of Mixing, Aggregation, Reaction, and Breakup on Structure Formation." He holds a BS in chemical engineering from the University of Mar del Plata, Argentina. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here